Article

From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

Author(s):

Debu Tripathy

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Related Videos
1 expert is featured in this series.
Image of a smiling woman with brown hair.
Image of a woman with short brown hair, wearing glasses.
Image of man with brown hair.
Image of woman with blonde hair.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Related Content
"FDA" text.
December 18th 2024

FDA Approves Ensacove for ALK-Positive NSCLC

Alex Biese
The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK-inhibitor.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Illustration of a man with dark hair and a dark goatee, wearing rectangular glasses.
December 18th 2024

A Holiday Poem: Who Says Cancer Doesn’t Rhyme?

Burt Rosen
The holiday season is here, so here’s a festive poem to remind us that cancer should not control us during this time.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of red blood cells.
December 18th 2024

Imbruvica-Venetoclax Shows Promise in Managing CLL

Spencer Feldman
A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.
Image of a doctor holding a surgical instrument with a gloved hand.
December 17th 2024

Surgical Intervention May Improve Survival in Young Patients with Breast Cancer

Tim Cortese
Younger patients with breast cancer and the BRCA gene showed improved survival after undergoing risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy.